BrainsWay Ltd.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
As hopes for a U.S.-Iran peace deal buoy investor sentiment, most Gulf markets have seen gains, with Dubai's main share index rising by 1.1% and Abu Dhabi's index up by 0.5%. In this context of easing geopolitical tensions and improved risk appetite, identifying promising stocks involves looking for those that can capitalize on regional stability and economic growth prospects.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $15 to $17.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic
BrainsWay Ltd (BRSYF) reports a 35% revenue increase and strategic advancements in mental health solutions, despite rising expenses and market uncertainties.
Brainsway (NASDAQ:BWAY) reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base. Chief Executive Officer Hadar Levy said on the company’s earnings call that rev
BrainsWay (NASDAQ:BWAY) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://viavid.webcasts.com/starthere.jsp?ei=1760244&tp_key=9c697b1af2 Summary Brainsway Ltd reported a 35% increase in revenue for Q1 2026, reaching $15.5 million, driven b
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call May 13, 2026 8:30 AM EDTCompany ParticipantsHadar Levy - Chief Executive OfficerIdo Marom - Chief Financial...
BrainsWay (NASDAQ:BWAY) affirms FY2026 sales outlook from $66.000 million-$68.000 million to $66.000 million-$68.000 million vs $66.350 million estimate.
BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 200 percent increase over earnings of $0.02 per share from the same
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.
RCMT, BWAY, FLOC, BTSG and GRC surge on strong momentum, with sharp price gains and rising earnings estimates signaling potential for continued upside.
Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Medical Products stocks face tariff and cost pressures, but Phibro Animal Health and peers leverage innovation, AI and demand trends to drive growth.
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
BrainsWay (BWAY) shows strong growth in TMS and new indications, but high costs, psychedelic competition, and stretched valuation raise riskâread before...
The Middle East market has recently seen a positive uptick, with Gulf bourses closing higher amid hopes for renewed U.S.-Iran peace talks, which have bolstered investor sentiment across the region. In this environment of optimism and easing regional tensions, identifying promising stocks involves looking for companies with strong domestic fundamentals and resilience to geopolitical fluctuations.
BrainsWay (BWAY) shows 27% revenue growth and a high-margin leasing model with recurring revenue, but shares trade at a premium.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | 0.07 | — | — |
| 2026-05-13 | 0.05 | 0.06 | +20.00% |
| 2026-03-11 | 0.03 | 0.06 | +155.36% |
| 2025-11-11 | 0.02 | 0.02 | -14.27% |
| 2025-08-13 | 0.02 | 0.03 | +53.85% |
| 2025-05-13 | 0.01 | 0.01 | -14.31% |
| 2025-03-11 | 0.01 | 0.02 | +100.00% |
| 2024-11-12 | 0.01 | 0.01 | +100.00% |
| 2024-08-06 | — | 0.01 | +900.00% |
| 2024-05-08 | -0.01 | — | +100.00% |
| 2024-03-06 | -0.01 | — | +100.00% |
| 2023-11-15 | -0.02 | — | +82.27% |
| 2023-08-09 | -0.04 | -0.02 | +40.48% |
| 2023-05-17 | -0.05 | -0.04 | +33.33% |
| 2023-03-15 | -0.06 | -0.06 | +6.25% |
| 2022-11-16 | -0.03 | -0.07 | -141.94% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BWAY | -5.64% | +37.10% | +67.09% | +211.57% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -8.61% | +41.74% | +70.53% | +198.88% |